Economic outcomes associated with diagnosed behavioral symptoms among patients with dementia in the United States: a health care claims database analysis.


Journal

BMC geriatrics
ISSN: 1471-2318
Titre abrégé: BMC Geriatr
Pays: England
ID NLM: 100968548

Informations de publication

Date de publication:
17 02 2023
Historique:
received: 03 10 2022
accepted: 30 01 2023
entrez: 16 2 2023
pubmed: 17 2 2023
medline: 22 2 2023
Statut: epublish

Résumé

Behavioral symptoms are common in patients with dementia. However, there is limited evidence of their economic burden. Among commercially insured patients with dementia in the United States, this study assessed the prevalence of diagnosed behavioral symptoms and whether healthcare resources utilization and costs were associated with these symptoms. This retrospective observational study was conducted using the IBM® MarketScan® Commercial Claims and Encounters and Medicare Supplemental database from October 1, 2015, to September 30, 2019. Diagnoses of dementia and behavioral symptoms were identified using the International Classification of Diseases, 10 Of the 62,901 patients with dementia included in the analysis, 16.5% had diagnosed behavioral symptoms 12 months post dementia diagnosis. Patients with diagnosed behavioral symptoms used more health care resources (mean annual pharmacy visits per patient: 39.83 vs. 33.08, mean annual outpatient visits per patient: 24.20 vs. 16.94, mean annual inpatient visits per patient: 0.98 vs. 0.47, mean annual ER visits per patient: 2.45 vs. 1.21) and incurred higher cost of care than those without diagnosed behavioral symptoms (mean annual total health care costs per patients: $63,268 versus $33,383). Inpatient care was the most significant contributor to total costs (adjusted annual mean cost per patient: $28,195 versus $12,275). Behavioral symptoms were significantly associated with higher healthcare resource utilization and costs among patients with dementia. Further research is warranted to address the unmet medical needs of this patient population.

Sections du résumé

BACKGROUND
Behavioral symptoms are common in patients with dementia. However, there is limited evidence of their economic burden. Among commercially insured patients with dementia in the United States, this study assessed the prevalence of diagnosed behavioral symptoms and whether healthcare resources utilization and costs were associated with these symptoms.
METHODS
This retrospective observational study was conducted using the IBM® MarketScan® Commercial Claims and Encounters and Medicare Supplemental database from October 1, 2015, to September 30, 2019. Diagnoses of dementia and behavioral symptoms were identified using the International Classification of Diseases, 10
RESULTS
Of the 62,901 patients with dementia included in the analysis, 16.5% had diagnosed behavioral symptoms 12 months post dementia diagnosis. Patients with diagnosed behavioral symptoms used more health care resources (mean annual pharmacy visits per patient: 39.83 vs. 33.08, mean annual outpatient visits per patient: 24.20 vs. 16.94, mean annual inpatient visits per patient: 0.98 vs. 0.47, mean annual ER visits per patient: 2.45 vs. 1.21) and incurred higher cost of care than those without diagnosed behavioral symptoms (mean annual total health care costs per patients: $63,268 versus $33,383). Inpatient care was the most significant contributor to total costs (adjusted annual mean cost per patient: $28,195 versus $12,275).
CONCLUSION
Behavioral symptoms were significantly associated with higher healthcare resource utilization and costs among patients with dementia. Further research is warranted to address the unmet medical needs of this patient population.

Identifiants

pubmed: 36797678
doi: 10.1186/s12877-023-03780-x
pii: 10.1186/s12877-023-03780-x
pmc: PMC9936641
doi:

Types de publication

Observational Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

99

Informations de copyright

© 2023. The Author(s).

Références

Prim Care Companion J Clin Psychiatry. 2001 Jun;3(3):93-109
pubmed: 15014607
J Alzheimers Dis Rep. 2021 Jun 17;5(1):535-540
pubmed: 34368636
N Engl J Med. 2013 Apr 4;368(14):1326-34
pubmed: 23550670
J Alzheimers Dis. 2021;81(4):1567-1578
pubmed: 34057080
J Clin Psychiatry. 2008 Mar;69(3):341-8
pubmed: 18294023
BMJ. 2015 Mar 02;350:h369
pubmed: 25731881
Int J Geriatr Psychiatry. 2006 Oct;21(10):972-6
pubmed: 16955429
BMJ Open. 2016 Nov 18;6(11):e013591
pubmed: 27864252
J Neurol Neurosurg Psychiatry. 2006 Feb;77(2):146-8
pubmed: 16421113
Am J Psychiatry. 2015 May;172(5):460-5
pubmed: 25585033
BMC Neurol. 2019 Feb 28;19(1):33
pubmed: 30819136
J Alzheimers Dis. 2009;18(1):11-30
pubmed: 19542627
Aging Ment Health. 2021 Mar;25(3):512-520
pubmed: 31847539
J Alzheimers Dis. 2021;83(1):89-101
pubmed: 34250934
Int J Geriatr Psychiatry. 2006 Jan;21(1):50-6
pubmed: 16323256
Arch Neurol. 2007 Dec;64(12):1755-61
pubmed: 18071039
Eur Psychiatry. 2005 Nov;20(7):490-6
pubmed: 16310680
Dialogues Clin Neurosci. 2003 Mar;5(1):49-59
pubmed: 22034255
Lancet Public Health. 2022 Feb;7(2):e105-e125
pubmed: 34998485
Front Neurol. 2012 May 07;3:73
pubmed: 22586419
Am J Geriatr Psychiatry. 2010 Oct;18(10):917-27
pubmed: 20808108

Auteurs

Rezaul Karim Khandker (RK)

Center of Observational and Real-World Evidence, Merck & Co., Inc, 351 North Sumneytown Pike, North Wales, PA, USA.

Farid Chekani (F)

Center of Observational and Real-World Evidence, Merck & Co., Inc, 351 North Sumneytown Pike, North Wales, PA, USA. farid.chekani@merck.com.

Kirti Mirchandani (K)

Complete HEOR Solutions (CHEORS), Chalfont, PA, USA.

Niranjan Kathe (N)

Complete HEOR Solutions (CHEORS), Chalfont, PA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH